Triptorelin: what it is and what the evidence says
A GnRH agonist. After an initial surge, sustained stimulation desensitises the pituitary and ends up SUPPRESSING the gonadotropins.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Hormones work in axes: a signal from the brain tells a gland to release another hormone, and so on down the chain, with brakes that shut the process off. Intervening at one point has consequences both upstream and downstream. That is why this is the group where professional assessment stops being a recommendation and becomes essential.
What it is studied for
Oncology, endometriosis, precocious puberty.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
Solid clinical evidence within its approved indications: phase 3 trials in advanced prostate cancer, premenopausal breast cancer, endometriosis, central precocious puberty, and preservation of ovarian function during chemotherapy.
The limitation that matters most
Here is the difference that matters: it is a GnRH AGONIST, meaning it produces an initial surge and then pituitary desensitisation amounting to chemical castration. What is sold on forums to 'restart the axis' after a steroid cycle has no trials behind it, and its documented effect beyond the acute phase is suppressive, not stimulatory.
Regulatory status
Approved (FDA, EMA, COFEPRIS) for oncology, endometriosis and precocious puberty. Banned in sport for males (WADA S2).
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
A prescription medicine that suppresses the axis. Its use on forums as post-cycle therapy has no backing.
Any plan involving it belongs with an endocrinologist or a urologist, especially where hypogonadism is suspected, because the suppressive effect on the axis lingers long after the last administration.
What this page cannot give you
A reference page can take you this far. You know what Triptorelin is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancerhuman J Clin Oncol · 2012 · PMID 22231041 →
- Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudyhuman J Clin Oncol · 2016 · PMID 26729437 →
- Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patientshuman ESMO Open · 2025 · PMID 39754976 →
- Endocrine Responses to Triptorelin in Healthy Women, Women With Polycystic Ovary Syndrome, and Women With Hypothalamic Amenorrheahuman J Clin Endocrinol Metab · 2023 · PMID 36653328 →
- Triptorelin for the treatment of endometriosisreview Expert Opin Pharmacother · 2014 · PMID 24832495 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Triptorelin or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Triptorelin?
A GnRH agonist. After an initial surge, sustained stimulation desensitises the pituitary and ends up SUPPRESSING the gonadotropins. It is studied within the area of hormonal/sexual.
Is there human evidence for Triptorelin?
Solid clinical evidence within its approved indications: phase 3 trials in advanced prostate cancer, premenopausal breast cancer, endometriosis, central precocious puberty, and preservation of ovarian function during chemotherapy.
Is it approved by any health agency?
Approved (FDA, EMA, COFEPRIS) for oncology, endometriosis and precocious puberty. Banned in sport for males (WADA S2).
What is the dose of Triptorelin?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Triptorelin is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.